OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor. 

Indexing:

Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Advances in Hematopoietic Stem Cell Transplantation

Submission Deadline: March 15, 2022 (Open) Submit Now

Guest Editor

Alessandra Picardi, PhD

1. Università degli Studi di Roma "Tor Vergata", Rome, Italy.
2. Director of  Haematology and Stem Cell Transpant Unit of AORN Cardarelli, Naples, Italy.

Website | E-Mail

Research Interests: Allogeneic Stem cell transplantation; Haematopoietic Stem Cell Donors; Autologous Stem Cell Transplantation

About This Topic

Hematopoietic Stem Cell Transplantation (HSCT) represents a therapeutic option for several neoplastic and non neoplastic haematological diseases. Many discoveries have been made in the last decades both in the autologous and allogeneic setting. Nowadays, the toxicity of the autologous HSCT is limited to a very small proportion of patients with a non relapse mortality rate < 5%, regardless the patient’s age. The new antibotics and antifungal drugs reduced the infectious mortality even in patients colonized by multi-resistant germs. The EBMT and CIBMTR activity survey of 2019 counts 25018 and 14270 autologous HSCT in 700 and 190 transplant teams, respectively.

Moreover, the advances in the supportive care, the modulation of the conditioning regimens, the better graft versus host disease (GVHD) control toghether with a wider donor’s choice has also increased the safety and the application of allogeneic HSCT. Thanks to theese progresses, even elderly up to 75-80 years perform the allogeneic HSCT and a suitable donor may be identified for almost all patients. The EBMT and CIBMTR activity survey of 2019 counts 18563 and 9498 first allogeneic HSCT, respectively. In the United States, it is worth to note that in 2019, 26% of allogeneic transplant recipients were age 65 and older.

In this context, the aim of this issue consists to point out the main advances in the HSCT setting.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Original Research

Evaluation of Total Parenteral Nutrition in the Autologous Transplantation Setting in Patients with AML: A Retrospective Exploratory Analysis

Received: 29 July 2023;  Published: 04 February 2024;  doi: 10.21926/obm.transplant.2401206

Abstract

Malnutrition remains a clinical challenge in AML patients undergoing autologous hematopoietic stem cell transplantation (ASCT), leading to physical deconditioning and prolonged hospitalization. Prospective data are mainly lacking to identify those patients who may particularly benefit from parenteral nutrition in this setting. This observation [...]
Open Access Short Communication

Promising Tactics with Certain Probiotics for the Treatment of Nephropathy in Hematopoietic Stem Cell Transplantation

Received: 02 May 2022;  Published: 30 August 2022;  doi: 10.21926/obm.transplant.2203165

Abstract

Hematopoietic stem cell transplantation (HSCT) is a standard form of cellular therapy for patients suffering from malignant hematological diseases. However, graft-versus-host disease (GVHD) is a very serious complication and a major cause of morbidity and mortality after allogeneic HSCT. Calcineurin inhibitors, such as cyclosporine, are widel [...]
Newsletter

TOP